Slingshot Insights | Alt Overview

ALT Overview

Upcoming Projects (ALT)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ALT)

Discussing Altimmune's GLP-1/glucagon dual receptor agonist candidate, pemvidutide, and the 48-week data from the Phase 2 MOMENTUM trial presented at the American Diabetes Association’s (ADA) 84th Scientific Sessions
Ticker: ALT
Executed On: Jul 02, 2024 at 12:30 PM EDT
Advancing Chronic Hepatitis B Treatment: In-Depth Analysis of Altimmune, Inc.'s HepTcell Ahead of Phase 2 Results Announcement
Ticker: ALT
Executed On: Mar 12, 2024 at 02:00 PM EDT
Discussing the clinical landscape of NASH and the potential of Akero's Efruxifermin & Altimmunes Pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: AKRO, ALT
Executed On: Nov 01, 2022 at 10:30 AM EDT

Upcoming & Overdue Catalysts (ALT)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (ALT)

Don’t see a strategic initiative related to the company you care about? Create your own!